Risperidone for bipolar disorders

Expert Review of Neurotherapeutics

Volumn 5, Issue 2, 2005, Pages 177-187

  Sajatovic, Martha ^a   Madhusoodanan, Subramoniam ^b   Fuller, Matthew A ^c   Aulakh, Lakynetiew ^d   Keaton, Daniel B ^d  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

^c UNIVERSITY OF TOLEDO   (United States)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Atypical antipsychotic; Bipolar disorder; Clinical trial; Mania; Risperidone

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; LITHIUM; RISPERIDONE; VALPROIC ACID;

BIPOLAR DISORDER; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG TOLERABILITY; DYSPEPSIA; EXTRAPYRAMIDAL SYMPTOM; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; HYPERKINESIA; INSOMNIA; MANIA; NAUSEA; PHARMACODYNAMICS; REVIEW; SIDE EFFECT; SOMNOLENCE; TREMOR;

ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; BLOOD GLUCOSE; BODY WEIGHT; CLINICAL TRIALS; DRUG EVALUATION; DRUG THERAPY, COMBINATION; EXPERT TESTIMONY; HUMANS; LIPIDS; PRACTICE GUIDELINES; PRODUCT SURVEILLANCE, POSTMARKETING; PROLACTIN; RISPERIDONE; TIME FACTORS;

EID: 15944422222     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.5.2.177     Document Type: Review

References (51)

1. Risperidone (Risperdal®) product information. Janssen Pharmaceutical Products, NJ, USA (2003).
2. Regier DA, Narrow WE, Rae DS, Manderscheid RW, Locke BZ, Goodwin FK. The de facto mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch. Gen. Psych. 50(2), 85-94 (1993).
3. Hirschfeld RM, Calabrese JR, Weissman MM et al. Screening for bipolar disorder in the community. J. Clin. Psychiatry 64(1), 53-59 (2003).
4. Pope HG Jr, McElroy SL, Keck PE Jr, Hudson JI. Valproate in the treatment of acute mania. A placebo-controlled study. Arch. Gen. Psych. 48(1), 62-68 (1991).
5. Bowden CL, Brugger AM, Swann AC et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA 271(23), 918-924 (1994).
6. Calabrese JR, Bowden CL, Sachs G et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J. Clin. Psychiatry 64(9), 1013-1024 (2003).
7. Bowden C, Calabrese JR, Sachs G et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch. Gen. Psych. 60(4), 392-400 (2003).
8. Yatham LN. Newer anticonvulsants in the treatment of bipolar disorder. J. Clin. Psychiatry 65(Suppl. 10), 28-35 (2004).
9. Zyprexa Prescribing Information. Eli Lilly and Company, IN, USA (2004).
10. Leysen JE, Janssen PM, Megens AA, Schotte A. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J. Clin. Psychiatry 55(Suppl.), 5-12 (1994).
11. 2C-adrenoceptor blockade by clozapine and other antipsychotic drugs. Eur. J. Pharmacol. 462(1-3), 33-40 (2003).
12. Pania L, Gessab GL. Dopaminergic deficit and mood disorders. Int. Clin. Psychopharmacol. 17(Suppl. 4), S1-S7 (2002).
13. Hirschfeld RM, Keck PE Jr, Kramer M et al. Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Am. J. Psychiatry 161(6), 1057-1065 (2004). Pivotal double-blind trial in bipolar mania.
14. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (Revision). American Psychiatric Press, Washington DC, USA (2002). Detailed practice guideline for bipolar disorder.
15. Sajatovic M, Blow FC, Ignacio RV, Kales HC. Age-related modifiers of clinical presentation and health service use among veterans with bipolar disorder. Psychiatr. Serv. 55(9), 1014-1021 (2004).
16. Lasser RA, Ramstack JM, Grandolfi GP, Mannaert E, Hoore PD. Long-acting injectable risperidone (Risperdal®Consta): manufactured using medisorb® microsphere technology, pharmacokinetics, and injection site assessments. Presented at the International Congress of Schizophrenia Research. CO, USA, March 29 - April 2 (2003).
17. Package Insert. Risperdal Consta (risperidone). Janssen Pharmaceutical Products, NJ, USA (2003).
18. Ravindran A, Silverstone P, Lacroix D, van Schaick E, Vermeulen A, Alexander J. Risperdone does not affect steady-state pharmacokinetics of divalproex sodium in patients with bipolar disorder. Clin. Pharmacokinet. 43(11), 733-740 (2004).
19. Bozikas V, Petrikis P, Karavatos A. Urinary retention caused after fluoxetine-risperidone combination. J. Psychopharmacol. 15(2), 142-143 (2001).
20. Spina E, Avenoso A, Facciola G, Scordo MG, Ancione M, Madia A. Plasma concentrations of risperidone and 9-hydroxyrisperidonc during combined treatment with paroxetine. Ther. Drug Monit. 23(3), 223-227 (2001).
21. Khanna S, Vieta E, Lyons B et al. Risperidone monotherapy in acute bipolar mania (Poster). Fifth International conference on bipolar disorder (ICBD), Pittsburgh, PA, USA (2003).
22. Smulevich AB, Khanna S, Eedekens M. Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol European Neuropsychopharmacology 15, 75-84 (2005)
23. Segal J, Berk M, Brook S. Risperidone compared with both lithium and haloperidol in mania: a double-blind, randomized controlled trial. Clin. Neuropharmacol. 21(3), 176-180 (1998).
24. Vieta E, Bruge E, Goikolea JM et al. Acute and continuation risperidone montherapy in mania. Human Psychopharmacology 19(1), 41-45 (2004)
25. Hirschfeld R, Vornic, Ksarcher K et al. Risperidone monotherapy in acute bipolar mania: a 9-week extension trial. New research poster presented at the American College of Neruopsychopharmacology 42nd Annual Meeting (ACNP). San Juan, Puerto Rico (2003)
26. Licht RW, Bysted M, Christensen H. Fixed-dose risperidone in mania: an open experimental trial. Int. Clin. Psychopharmacol. 16(2), 103-110 (2001).
27. Yatham LN, Grossman F, Augustyns I, Vieta E, Ravindran A. Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomized controlled trial. Br. J. Psychiatry 182, 141-147 (2003).
28. Sachs GS, Grossman F, Ghaemi SN, Okamoto A, Bowden CL. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am. J. Psychiatry 159(7), 1146-1154 (2002). Pivotal combination therapy trial in bipolar disorder.
29. Petrie W. Risperidone versus olanzapine as adjunctive therapy in the treatment of patients with bipolar disorder who are recieivng a primary thymoleptic agent. American Psychiatric Association 157th Annual Meeting. NY, USA, May 1-6 (2004).
30. Vieta E, Herraiz M, Parramon G, Goikolea JM, Fernandez A, Benabarre A. Risperidone in the treatment of mania: efficacy and safety results from a large, multicentre, open study in Spain. J. Affect. Disord. 72(1), 15-19 (2002).
31. Bowden CL, Myers JE, Grossman F, Xie Y. Risperidone in combination with mood stabilizers: a 10-week continuation phase study in bipolar I disorder. J. Clin. Psychiatry 65(5), 707-714 (2004).
32. Yatham LN, Binder C, Riccardelli et al. Risperidone in acute and continuation treatment of mania. Int. Clin. Psychopharmacol 18(4), 227-235 (2003)
33. Vieta E, Goikolea JM, Corbella B et al. Risperidone safety and efficacy in the treatment of bipolar and schizoaffective disorders: results from a 6-month, multicenter, open study. J. Clin. Psychiatry 62(10), 818-825 (2001). Longer-term trial of risperidone in bipolar disorder.
34. Stahl SM, Shelton RC. Risperidone with and without paroxetine compared to paroxetine alone for bipolar depression. 41st Annual meeting of the American College of Neuropsychopharmacology (ACNP). Hawaii, USA (2001).
35. McIntyre RS, Mancini DA, Srinivasan J, McCann S, Konarski JZ, Kennedy SH. The antidepressant effects of risperidone and olanzapine in bipolar disorder. Can. J. Clin. Pharmacol. 11(2), e218-e226 (2004).
36. Shelton RC, Stahl SM. Risperidone and paroxetine given singly and in combination for bipolar depression. J. Clin. Psychiatry 65(12) 1715-1719 (2004).
37. American Diabetes Association; America Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27(2), 596-601 (2004). Key consensus publication on the growing attention and concern about the association of antipsychotic medication, obesity and diabetes.
38. Guille C, Sachs GS, Ghaemi SN. A naturalistic comparison of clozapine, risperidone and olanzapine in the treatment of bipolar disorder. J. Clin. Psychiatry 61(9), 638-642 (2000).
39. Ghaemi SN, Hsu DJ, Rosenquist KJ, Katzow JJ, Goodwin FK. Long-term observational comparison of risperidone and olanzapine in bipolar disorder. Ann. Clin. Psychiatry 16(2), 69-73 (2004).
40. Turrone P, Kapur S, Seeman MV, Flint AJ. Elevation of prolactin levels by atypical antipsychotics. Am. J. Psychiatry 159(1), 133-135 (2002).
41. Gianfrancesco F, Grogg A, Mahmoud R, Wang RH, Meletiche D. Differential effects of antipsychotic agents on the risk of development of Type 2 diabetes mellitus in patients with mood disorders. Clin. Ther. 25(4), 1150-1171 (2003).
42. Lindenmayer JP, Czobor P, Volavka J et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am. J. Psychiatry 160(2), 290-296 (2003).
43. Kupfer DJ, Frank E, Grochocinski VJ, Cluss PA, Houck PR, Stapf DA. Demographic and clinical characteristics of individuals in a bipolar disorder case registry. J. Clin. Psychiatry 63(2), 120-125 (2002).
44. Zarate CA, Quiroz JA. Combination treatment in bipolar disorder: a review of controlled trials. Bipolar Disord. 5(3), 217-225 (2003).
45. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition (DSM-IV-TR). American Psychiatric Press, Washington DC, USA (2000).
46. Gelenberg AJ, Pies R. Matching the bipolar patient and the mood stabilizer. Ann. Clin. Psychiatry 15(3-4), 203-216 (2003).
47. Keith SJ, Pani L, Nick B. Practical application of pharmacotherapy with long-acting risperidone for patients with schizophrenia. Psychiatr. Serv. 55(9), 997-1005 (2004).
48. Colora F, Vieta E. Treatment adherence in bipolar patients. Clin. Approaches Bipolar Dis. 1(2), 49-56 (2002).
49. Suppes T, Baldessarini RJ, Faedda GL, Tohen M. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch. Gen. Psych. 48(12), 1082-1088 (1991).
50. Adams J, Scott J. Predicting medication adherence in severe mental disorders. Acta Psychiatr. Scand. 101(2), 119-124 (2000).
51. Muller-Oerlinghausen B, Muser-Causemann B, Volk J. Suicides and parasuicides in a high-risk patient group on and off lithium long-term medication. J. Affect. Disord. 25(4), 261-269 (1992).